Description
Tirzepatide is a GLP-1 receptor agonist developed for the treatment of type 2 diabetes mellitus. This medication mimics the hormone GLP-1 to improve glycemic control and promote weight loss. Tirzepatide has undergone extensive testing, including animal reproduction studies and clinical trials, and has shown to be safe and effective. The medication has already surpassed clinical trials and has been approved by the FDA for use in the United States.
As a GLP 1 receptor agonist, it works by mimicking the effects of the hormone GLP-1 in the body. Tirzepatide binds to GLP-1 receptors in the body and activates them, leading to similar effects as GLP-1. GLP-1 is a naturally occurring hormone that stimulates the release of insulin from the pancreas, reduces the amount of glucose produced by the liver, and slows down the absorption of glucose from the gut. This results in lower blood sugar levels and improved insulin sensitivity. In addition to its GLP-1 receptor activity, Tirzepatide also has activity on another hormone called glucose dependent insulinotropic polypeptide (GIP). GIP stimulates insulin secretion from the pancreas and promotes fat storage, but Tirzepatide reduces the effects of GIP to promote weight loss.
The recommended starting dose of tirzepatide is 5 mg once a week, which can be increased to 10 mg once a week after 4 weeks. Another dose escalation of 15mg once a week for 4 additional weeks is also acceptable. Routine monitoring of blood glucose and body weight is recommended, and missed doses should be taken as soon as possible within 5 days of the missed dose.
